Genmab Files IND for HuMax-CD20 to Treat Non-Hodgkin's Lymphoma COPENHAGEN, Denmark, December 19 /PRNewswire/ -- Summary: Genmab Is Filing an Investigational New Drug Application (IND) in the US and a Clinical Trial Application (CTA) in England Today to Start an Open Label Phase I/II Clinical Trial Using HuMax-CD20 to Treat Non-Hodgkin's Lymphoma Genmab A/S (CSE: GEN) announced that it is filing an IND today in the US and a CTA in England to start an open label Phase I/II clinical trial using HuMax-CD20 in patients with relapsed or refractory follicular lymphoma. Follicular lymphoma is the second most common lymphoma in US and Europe, accounting for 11% to 35% of all non- Hodgkin's lymphoma. The trial is expected to include 40 patients, and will be a dose escalation study. Patients will receive 4 weekly doses of either 300, 500, 700 or 1000mg of HuMax-CD20 with a total of 10 patients treated at each dose level. The primary objective will be to assess the safety and the efficacy of HuMax-CD20. "HuMax-CD20 has performed well in a variety of pre-clinical tests," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We are very happy with the progress made to date and are eager to advance HuMax-CD20 to Phase I/II clinical trials." About HuMax-CD20 HuMax-CD20 is a human antibody which is effective at binding to the disease target, and releases only very slowly from the target over time. In February 2003, Genmab presented data from pre-clinical laboratory tests showing HuMax-CD20 appeared to kill tumour cells that were resistant to rituximab, a marketed cancer therapy. The data showed the antibody highly effective in inducing complement mediated cytotoxicity (cell destruction) of B-cell tumours. Subsequently, Genmab has collected data that appears to show HuMax-CD20 is also effective in inducing Natural Killer cell- mediated cytotoxicity of B-cell tumours. Further, in a 92 day primate study, HuMax-CD20 effectively depleted B-cells from blood and lymph nodes. In this study, HuMax-CD20 appeared to deplete B- cells for a period of time that was four times longer than rituximab. In another study it was found that HuMax-CD20 binds to a unique site on CD20 target cells when compared to other known CD20 antibodies. This is a distinguishing characteristic of HuMax-CD20 and may help explain why HuMax-CD20 has outperformed other CD20 antibodies in a variety of pre-clinical studies. Furthermore, in a novel cancer disease model in immuno-compromised mice using sensitive bio-luminescence imaging, new data show that HuMax-CD20 appears to stop growth of B-cell tumours grown from a laboratory cell line far more effectively than either placebo, or a marketed treatment, rituximab. About CD20 The CD20 antigen is a transmembrane protein on pre-B and mature B lymphocytes. CD20 appears to act as a calcium ion channel, and to regulate early steps in B lymphocyte activation. The molecule is not shed from the cell surface, and is not internalized upon antibody binding. CD20 is found on over 90% of B-cell lymphomas, as well as other lymphoid tumors of B-cell origin. About Genmab A/S Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(TM) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquartered in Copenhagen, Denmark and has operations in Utrecht, The Netherlands and Princeton, New Jersey in the US. For more information about Genmab, visit www.genmab.com. Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements, e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law. DATASOURCE: Genmab A/S Contact: Sisse P. Hansen, Investor & Public Relations of Genmab A/S, T: +45 33 44 77 76, M: +45 25 27 47 27, E: sha@genmab.com

Copyright